Bayer Schering Pharma has received approval from the U.S. Food and Drug Administration (FDA) for its new Natazia® pill for the prevention of pregnancy. This new product with an estradiol valerate/dienogest combination is the first in a new class of oral contraceptives to deliver estradiol. Natazia® is expected to be available in the United States this summer. Outside the U.S., the product has been marketed in a number of countries as Qlaira® since May 2009.
“We are very pleased that women in the U.S. now also have the option to choose our new oral contraceptive Natazia® as an effective option for the prevention of pregnancy,” said Phil Smits, MD, Head of Bayer Schering Pharma’s Women’s Healthcare business unit. “We are also working with the FDA on an indication for menstrual bleeding disorders to offer women a tailored therapy in future for this debilitating condition.”